Li J, Jiang Y, Ma M, Wang L, Jing M, Yang Z
J Transl Med. 2025; 23(1):135.
PMID: 39885578
PMC: 11783851.
DOI: 10.1186/s12967-025-06138-6.
Silva L, Cavallini E, da Silva R, SantAna M, Yoshikawa A, Salomao T
Pharmaceuticals (Basel). 2025; 18(1).
PMID: 39861087
PMC: 11768557.
DOI: 10.3390/ph18010024.
Panda V, Mishra B, Mahapatra S, Swain B, Malhotra D, Saha S
Cancers (Basel). 2025; 17(2).
PMID: 39858015
PMC: 11763662.
DOI: 10.3390/cancers17020234.
Eren E, Das J, Tollefsbol T
Nutrients. 2024; 16(23).
PMID: 39683540
PMC: 11644657.
DOI: 10.3390/nu16234143.
Lin S, Zhang H, Zhao R, Wu Z, Zhang W, Yu M
Sci Rep. 2024; 14(1):29545.
PMID: 39604504
PMC: 11603196.
DOI: 10.1038/s41598-024-80858-5.
Identification of as a potential therapeutic target via a novel cuproptosis-related gene signature for the prediction of liver cancer prognosis.
Xia C, Chen Y, Zhu Y, Chen D, Sun H, Shen T
J Gastrointest Oncol. 2024; 15(5):2230-2251.
PMID: 39554575
PMC: 11565118.
DOI: 10.21037/jgo-24-609.
Dissecting the Single-Cell Diversity and Heterogeneity Underlying Cervical Precancerous Lesions and Cancer Tissues.
Han Y, Shi L, Jiang N, Huang J, Jia X, Zhu B
Reprod Sci. 2024; .
PMID: 39354287
DOI: 10.1007/s43032-024-01695-5.
Mast cell heparanase promotes breast cancer stem-like features via MUC1/estrogen receptor axis.
Bongiorno R, Lecchi M, Botti L, Bosco O, Ratti C, Fontanella E
Cell Death Dis. 2024; 15(9):709.
PMID: 39349458
PMC: 11442964.
DOI: 10.1038/s41419-024-07092-9.
Immune and gene-expression profiling in estrogen receptor low and negative early breast cancer.
Massa D, Vernieri C, Nicole L, Criscitiello C, Boissiere-Michot F, Guiu S
J Natl Cancer Inst. 2024; 116(12):1914-1927.
PMID: 39083015
PMC: 11630536.
DOI: 10.1093/jnci/djae178.
The Complex Role of Mast Cells in Head and Neck Squamous Cell Carcinoma: A Systematic Review.
Tzorakoleftheraki S, Koletsa T
Medicina (Kaunas). 2024; 60(7.
PMID: 39064602
PMC: 11279237.
DOI: 10.3390/medicina60071173.
Towards targeting the breast cancer immune microenvironment.
Harris M, Savas P, Virassamy B, OMalley M, Kay J, Mueller S
Nat Rev Cancer. 2024; 24(8):554-577.
PMID: 38969810
DOI: 10.1038/s41568-024-00714-6.
Single-cell transcriptomic landscape and the microenvironment of normal adjacent tissues in hypopharyngeal carcinoma.
Guan R, Li C, Gu F, Li W, Wei D, Cao S
BMC Genomics. 2024; 25(1):489.
PMID: 38760729
PMC: 11100249.
DOI: 10.1186/s12864-024-10321-2.
Cellular interactions in tumor microenvironment during breast cancer progression: new frontiers and implications for novel therapeutics.
Akinsipe T, Mohamedelhassan R, Akinpelu A, Pondugula S, Mistriotis P, Avila L
Front Immunol. 2024; 15:1302587.
PMID: 38533507
PMC: 10963559.
DOI: 10.3389/fimmu.2024.1302587.
Identification of breast cancer subgroups and immune characterization based on glutamine metabolism-related genes.
Yu H, Liu J
BMC Med Genomics. 2024; 17(1):17.
PMID: 38200578
PMC: 10782609.
DOI: 10.1186/s12920-023-01792-5.
Impact of disulfidptosis-associated clusters on breast cancer survival rates and guiding personalized treatment.
Chen X, Hu G, Yu Q
Front Endocrinol (Lausanne). 2023; 14:1256132.
PMID: 38116315
PMC: 10728640.
DOI: 10.3389/fendo.2023.1256132.
Exploration of prognosis and immunometabolism landscapes in ER+ breast cancer based on a novel lipid metabolism-related signature.
Shen L, Huang H, Li J, Chen W, Yao Y, Hu J
Front Immunol. 2023; 14:1199465.
PMID: 37469520
PMC: 10352658.
DOI: 10.3389/fimmu.2023.1199465.
Overexpression of DBT suppresses the aggressiveness of renal clear cell carcinoma and correlates with immune infiltration.
Zhang C, Huang G, Yang J, Jiang Y, Huang R, Ye Z
Front Immunol. 2023; 14:1197011.
PMID: 37383233
PMC: 10293648.
DOI: 10.3389/fimmu.2023.1197011.
Frenemies in the Microenvironment: Harnessing Mast Cells for Cancer Immunotherapy.
Sulsenti R, Jachetti E
Pharmaceutics. 2023; 15(6).
PMID: 37376140
PMC: 10303176.
DOI: 10.3390/pharmaceutics15061692.
Elevated Mast Cell Abundance Is Associated with Enrichment of CCR2+ Cytotoxic T Cells and Favorable Prognosis in Lung Adenocarcinoma.
Fan F, Gao J, Zhao Y, Wang J, Meng L, Ma J
Cancer Res. 2023; 83(16):2690-2703.
PMID: 37249584
PMC: 10425735.
DOI: 10.1158/0008-5472.CAN-22-3140.
Precancerous Lesions of the Head and Neck Region and Their Stromal Aberrations: Piecemeal Data.
Harris A, Andl T
Cancers (Basel). 2023; 15(8).
PMID: 37190121
PMC: 10137082.
DOI: 10.3390/cancers15082192.